Last reviewed · How we verify
NCT05109572
The Impact of the Covid-19 Pandemic on Schizophrenia Patients Registered With the Community Mental Health Center
trial testing Hospitalized in Schizophrenia in 108 participants. Completed in 20 July 2021.
20 May 2021
Quick facts
| Lead sponsor | Dr. Lutfi Kirdar Kartal Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 108 |
| Start date | 20 March 2021 |
| Primary completion | 20 May 2021 |
| Estimated completion | 20 July 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Hospitalized
- Non-hospitalized with emergency care
- Non-hospitalized and non-emergency care
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to examine the effect of the Covid-19 pandemic on schizophrenia patients registered to the Community Mental Health Center (CMHC) in terms of depression, suicide risk, and tendency to violence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05109572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Dr. Lutfi Kirdar Kartal Training and Research Hospital trials
Trials by the same sponsor.
- NCT07322497 — Comparison of Video Based Phone App vs. Supervised Preoperative Exercise for ACL Reconstruction · NA · not yet recruiting
- NCT07141966 — Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophren · completed
- NCT07142018 — Investigation of the Effect of Hyperbaric Oxygen Therapy in Patients With Avascular Necrosis · active not recruiting
- NCT07144553 — Relationship Between Eating Disorders, Anthropometric Characteristics, and Physical Activity After Bariatric Surgery · completed
- NCT07140042 — Physical Fitness, Physical Activity Level, Depression and Quality of Life in Bipolar and Schizophrenia Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05109572 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Lutfi Kirdar Kartal Training and Research Hospital
- Last refreshed: 5 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing